Physician profile
Vidal Espeleta
NPI 1245327808
$9,927.29
in general payments reported to CMS, 2019-2025
49 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,584 · 2020: $661 · 2021: $853 · 2022: $1,781 · 2023: $2,029 · 2024: $1,313 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,902 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,902.01 |
| Education | $146.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,495.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,337.28 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Intuitive Surgical, INC. | $817.85 | 2022-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $809.02 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Inari Medical, INC. | $409.30 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Harmony Biosciences LLC | $340.20 | 2021-2025 | Wakix |
| Insmed, INC. | $250.54 | 2021-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $240.86 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Pulmonx Corporation | $230.20 | 2021-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Grifols USA, LLC | $192.28 | 2019-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $170.58 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Avadel Cns Pharmaceuticals, LLC | $154.74 | 2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $144.95 | 2022 | |
| Genzyme Corporation | $141.79 | 2019-2025 | |
| Lilly USA, LLC | $139.52 | 2025 | Zepbound |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidal Espeleta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.